Patients with type 2 diabetes are at increased susceptibility to a prolonged QT interval. Furthermore, insulin secretagogues, drugs used to treat diabetes, may prolong QT interval and provoke arrhythmias. We evaluated whether secretagogues can affect QTc interval during cardiac stress test in 20 patients with type 2 diabetes treated with secretagogues. ECG stress test was performed in all patients. QTc interval was calculated both before cardiac stress test (BCST) and at acme of cardiac stress test (ACST). Diabetic patients treated with secretagogues showed longer QTc-ACST values than those treated with metformin only. QTc-ACST values resulted shorter than QTc-BCST values in control group. Diabetic patients treated with secretagogues showed QTc-ACST values significantly longer than QTc-BCST values. In our study, diabetic patients treated with secretagogues did not show the QTc physiologic decrease that is a protective against arrhythmias. These results suggest to evaluate, in these patients, QT length, even during routine cardiac stress test. © 2012 Springer-Verlag Italia.

Curione, M., Di Bona, S., Amato, S., Turinese, I., Tarquini, G., Gatti, A., et al. (2014). Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues. ACTA DIABETOLOGICA, 51(1), 31-33 [10.1007/s00592-012-0438-6].

Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues

Varrenti M.;
2014

Abstract

Patients with type 2 diabetes are at increased susceptibility to a prolonged QT interval. Furthermore, insulin secretagogues, drugs used to treat diabetes, may prolong QT interval and provoke arrhythmias. We evaluated whether secretagogues can affect QTc interval during cardiac stress test in 20 patients with type 2 diabetes treated with secretagogues. ECG stress test was performed in all patients. QTc interval was calculated both before cardiac stress test (BCST) and at acme of cardiac stress test (ACST). Diabetic patients treated with secretagogues showed longer QTc-ACST values than those treated with metformin only. QTc-ACST values resulted shorter than QTc-BCST values in control group. Diabetic patients treated with secretagogues showed QTc-ACST values significantly longer than QTc-BCST values. In our study, diabetic patients treated with secretagogues did not show the QTc physiologic decrease that is a protective against arrhythmias. These results suggest to evaluate, in these patients, QT length, even during routine cardiac stress test. © 2012 Springer-Verlag Italia.
Articolo in rivista - Articolo scientifico
Arrhythmias; ECG; Metformin; QT; Secretagogues; Type 2 diabetes; Aged; Arrhythmias, Cardiac; Carbamates; Diabetes Mellitus, Type 2; Electrocardiography; Female; Glyburide; Heart Rate; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Exercise Test
English
2014
51
1
31
33
none
Curione, M., Di Bona, S., Amato, S., Turinese, I., Tarquini, G., Gatti, A., et al. (2014). Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues. ACTA DIABETOLOGICA, 51(1), 31-33 [10.1007/s00592-012-0438-6].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/240747
Citazioni
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
Social impact